Casey Rodarmor, the chief coder behind the Bitcoin Ordinals protocol, announced Tuesday that he is proposing a significant change to the software, one that could be viewed with skepticism by its budding user base. Revealed in a post on X Tuesday, Rodarmor specifically proposed deprioritizing the canonical numbering system that assigns unique and coveted numbers to inscriptions
In a recent study published in the journal JAMA Network Open, researchers evaluated the performance of the electronic Clinical Dementia Rating (eCDR) against that of other clinically administered assessments, including Clinical Dementia Rating (CDR), for cognitive impairment and dementia screening among older adults. Study: Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening. Image
Google DeepMind has used its technology to identify parts of human DNA that might cause diseases. Source link
The City watchdog’s findings follow a row over threats to close Nigel Farage’s bank account. Source link
The government says 27 more educational settings in England are affected by crumbling concrete. Source link
Investors would have reason to be cautious on tech stocks: The sector already has seen big gains this year and there’s a chance interest rates could still go higher. Don’t fret, said analysts at Wedbush, because the artificial-intelligence-led … Source link
Sep 16, 2023, 01:12 PM ET DALLAS — Markieff Morris, the other player in the trade that brought Kyrie Irving to Dallas from Brooklyn, is re-signing with the Mavericks. The return of Morris was announced Saturday, a little more than two months after Irving agreed to stay with the Mavericks on a three-year, $120 million
The lawyer responsible for laundering $400 million from the OneCoin fraud has been denied a motion seeking a new trial, despite a prosecution witness having perjured themselves in the trial against him in 2019. According to a Sept. 18 report from Bloomberg, 54-year-old lawyer Mark Scott argued that he didn’t know OneCoin was a fraudulent
The company is working on wheat, soybean and maize, and has achieved increases of more than 20% in seed biomass, with field trials currently under evaluation. If all goes well, says Mr Hendron, crop plants could be available commercially by around 2030 or 2031. Source link
Investigational muvalaplin (Eli Lilly), the first oral therapy being developed to lower lipoprotein (a) levels, was shown to reduce levels in a phase 1 trial, with no safety concerns, researchers report. In a separate phase 2 study, olpasiran (Amgen), which is given by injection, lowered Lp(a) levels for nearly 1 year after the last dose,
